IPO: NAV per share grew 3% to 114p, with strong exits and broad portfolio progress in H1 2026
NAV per share rose to 114p in H1 2026, with strong cash realizations and portfolio progress. Key assets like Pfizer's obesity royalty and Oxford Nanopore drove value, while third-party capital and new mandates expanded. Execution, capital allocation, and value realization remain top priorities.Base…